Vice President, Pharmacology
Dr. Bissonnette oversees pharmacology and translational activities supporting the advancement of HUYABIO’s lead candidates and contributes to the assessment of new therapeutic opportunities in oncology and inflammation. Dr. Bissonnette has more than 20 years of drug discovery experience in oncology, inflammation and immunology, and has experience in small molecules, peptides, biologics and drug conjugates. Prior to joining HUYABIO, he was Associate Director/Oncology Therapeutic Area Lead at CovX Research (Pfizer WRD) and Associate Director, Molecular Biology/Oncology at Ligand Pharmaceuticals where he was responsible for oncology and inflammation drug discovery. He was a major contributor in the approvals and post approval development of Targretin and ONTAK. Dr. Bissonnette completed his BSc in Biochemistry and his PhD in Tumor Immunology at McGill University. He completed his postdoctoral training at the La Jolla Institute for Allergy and Immunology.